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Abstract Coronary microvascular dysfunction is a topic
that has recently gained considerable interest in the medical
community owing to the growing awareness that micro-
vascular dysfunction occurs in a number of myocardial
disease states and has important prognostic implications.
With this growing awareness, comes the desire to accu-
rately assess the functional capacity of the coronary
microcirculation for diagnostic purposes as well as to
monitor the effects of therapeutic interventions that are
targeted at reversing the extent of coronary microvascular
dysfunction. Measurements of coronary microvascular
resistance play a pivotal role in achieving that goal and
several invasive and noninvasive methods have been
developed for its quantiﬁcation. This review is intended to
provide an update pertaining to the methodology of these
different imaging techniques, including the discussion of
their strengths and weaknesses.
Keywords Coronary microvascular resistance 
Imaging  Perfusion
Introduction
The heart relies on myocardial perfusion for supply of
oxygen and substrates necessary to maintain contractile
function [11]. Under physiological conditions, perfusion is
tightly matched to metabolic demand. This is achieved by
modulating coronary vascular resistance through adjust-
ment of vascular tone. This process is under metabolic,
endothelial, myogenic, and neurohumoral control [5, 16,
70]. In the presence of a pathological increase in vascular
resistance, as that resulting from a stenosis of an epicardial
artery, regulatory mechanisms may become progressively
exhausted and blood supply may fall short relative to
demand, promptly resulting in myocardial ischemia as
myocardial oxygen extraction can only slightly increase in
ischemic conditions. Traditionally, identiﬁcation and
treatment of augmented coronary resistance have focused
on obstructive atherosclerosis of the epicardial arteries.
However, over the past two decades it has become
increasingly apparent that augmented vascular resistance
may also reside in the coronary microcirculation in a
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DOI 10.1007/s00395-009-0037-znumber of clinical conditions [13, 39]. Moreover, the
severity of coronary microvascular dysfunction has been
shown to be a powerful predictor of an adverse clinical
outcome [14, 78]. Consequently, accurate assessment of
coronary microvascular resistance (CMVR) has gained
considerable interest, including the identiﬁcation of
potentially modiﬁable determinants for therapeutic
purposes.
Conventional ﬂow reserve measurements, using inva-
sive and noninvasive techniques, are frequently used to test
the integrity of the microcirculation [95, 102]. As will be
discussed, however, their dependence on hemodynamic
conditions and cardiac function limits the conclusions that
can be derived from these measurements. Recent advances
in different imaging modalities offer the possibility to
quantify myocardial perfusion and resistance in absolute
terms and to correct for some of these confounders. This
review is intended to provide an update on the quantitative
assessment of CMVR, together with its strengths and
limitations, with particular emphasis on the noninvasive
approach.
Coronary microvascular resistance
Resistance equals pressure-gradient divided by ﬂow. In the
case of the heart, the mean aortic to coronary back pressure
(vide infra) gradient divided by total sinus coronary blood
ﬂow yields total coronary resistance (mmHg mL min
-1),
although it must be acknowledged that Thebesian ﬂow
draining directly to the ventricular and atrial cavities is
unaccounted for [93]. The coronary system can roughly be
divided into three separate resistance components, being
the conduit epicardial arteries, the arterioles, and the cap-
illary–venous compartment [70, 106]. Under normal
physiological conditions, resistance is principally deter-
mined by vasomotor regulation of the arterioles with a
diameter of less than 400 lm and ﬂow is kept constant over
a wide range of perfusion pressures, i.e., ﬂow is autoreg-
ulated [16, 70, 76, 118]. The control mechanisms involved
in autoregulation are numerous and have been reviewed
elsewhere [5, 44, 106]. The plateau level of resting ﬂow, as
depicted in Fig. 1, is matched to oxidative metabolism,
which in turn is predominantly determined by heart rate,
wall stress, and contractile state [11]. Therefore, knowl-
edge of coronary resistance under baseline conditions
mainly reﬂects basal metabolism, although it is also
inﬂuenced by vascular rarefaction in LV hypertrophy and
conditions where arterial oxygen content is reduced such as
anemia [12]. Only when faced with a subtotal stenosis of an
epicardial artery will coronary resistance be signiﬁcantly
augmented and cannot be compensated for by autoregula-
tion [108]. In the absence of collaterals, this condition
results in hampered resting perfusion and ultimately
invariably results in tissue necrosis, although mild reduc-
tions in resting ﬂow may be tolerated for an unknown
period of time [42, 119]. However, when autoregulation is
exhausted, minimal resistance can be calculated. Thus,
when one wants to evaluate the performance of the
microvascular bed and quantify minimal CMVR, the fol-
lowing conditions should ideally be met: (1) exclude the
presence of obstructive epicardial coronary artery disease
or determine driving pressure distal to an epicardial ste-
nosis, (2) quantify ﬂow, (3) induce maximal vasodilatation
while recording pressure and ﬂow, and (4) correct for
coronary back pressure. The latter parameter is, however,
difﬁcult to measure as it is composed of multiple hemo-
dynamic factors such as central venous pressure, coronary
venous pressure, extravascular compressive forces such as
LV end-diastolic pressure, and is further complicated by
zero ﬂow pressure [3]. As discussed below in more detail,
in clinical studies many investigators, therefore, assume it
to be zero or to be equivalent to right atrial pressure. In
Fig. 1 Autoregulation maintains ﬂow during constant metabolism.
Over the autoregulation range, i.e., the plateau of the autoregulation
curve, ﬂow is rather constant for a range of perfusion pressures.
The level of the plateau is related to the metabolic state of the heart.
The dashed line indicates maximal pharmacological vasodilation. The
dotted line shows the maximal physiological dilation, which is
slightly smaller than can be reached pharmacologically. The ﬂow
reserve is given by the ratio (B ? A)/A. Flow reserve is dependent on
the basal level of myocardial metabolism, irrespective of minimum
hyperemic coronary resistance. It should be noted that these relations
are derived from isolated heart preparation studies where perfusion
pressure and workload can be controlled independently. Human
physiology in vivo usually operates within a smaller range of pressure
and ﬂow, and the close correlation between systolic pressure and
oxidative metabolism results in a much narrower plateau phase of
relative constant ﬂow. Reprinted with permission from Westerhof
et al. [118]
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123conditions of high arterial perfusion pressure and low
coronary back pressure, this assumption is of little signi-
ﬁcance. In contrast, when arterial perfusion pressure is low,
e.g., distal to a signiﬁcant epicardial coronary stenosis, and/
or coronary back pressure is high, this approach will result
in potential erroneous quantiﬁcation of CMVR [118].
It is also important to realize that minimal CMVR is
governed by intravascular as well as extravascular forces
[118]. The former represents the conductance of the cor-
onary microvessels themselves, whereas the latter is
affected by mechanical cross-talk between contracting
myocardium and the coronary vasculature such as diastolic
perfusion time, cardiac contraction, and LV diastolic wall
stress [44, 118]. In other words, CMVR is determined not
only by intrinsic characteristics of the microvessels, but
also by cardiac function where increased intra- and extra-
myocardial forces of the beating heart can impede coronary
ﬂow.
Coronary ﬂow reserve
Coronary ﬂow reserve (CFR) is deﬁned as the ratio of peak
hyperemic to resting ﬂow. At a ﬁrst glance, a reduction in
ﬂow reserve seems indicative of an increase in minimal
coronary resistance and, in the absence of obstructive
epicardial coronary artery disease, is therefore frequently
used as an index of microvascular dysfunction. Of interest,
absolute quantiﬁcation of perfusion is not mandatory for
the calculation of CFR, as the ratio of semi-quantitative
perfusion indices will also yield a ﬂow ratio. Unfortu-
nately, as can be appreciated from Fig. 1, for a given level
of hyperemic ﬂow, CFR strongly depends on changes in
the plateau level of resting perfusion. Although normali-
zation of resting ﬂow for heart rate and blood pressure may
standardize this parameter, its correction remains incom-
plete. The magnitude of hyperemic perfusion, in turn, is
likewise affected by hemodynamic conditions such as
driving pressure and heart rate. The dependence of ﬂow
reserve on hemodynamic conditions and cardiac function
therefore limits its use as a reliable and reproducible
marker of microvascular disease [88]. Minimal CMVR
should therefore be considered a more quantitative measure
of microvascular function and the preferred parameter to
study microvascular disease.
Invasive quantiﬁcation of minimal CMVR
Invasive catheter-based quantiﬁcation of minimal CMVR
can be performed at a global or regional level [56, 101].
For the global approach, the coronary sinus is selectively
catheterized and ﬂow is measured with the use of the
thermodilution technique. This technique is based on the
general indicator dilution theory [74], which has been
validated in the human heart to quantify global myocardial
blood ﬂow [28]. After a bolus or continuous injection of
saline of a known volume and temperature, the temperature
curve registration, a few centimeters distal to the injection
site, allows for the computation of absolute volumetric
ﬂow, expressed in mL min
-1. The regional approach
requires catheterization of one of the major coronary
arteries and ﬂow can again be measured using the thermo-
dilution technique [82]. Alternatively, ﬂow velocity can be
measured with the use of a Doppler guide wire advanced
into the epicardial coronary artery [25]. Current state-of-
the-art single guide wires allow for the assessment of ﬂow
velocity and pressure simultaneously to determine CMVR
[2, 82, 98]. As the Doppler signal yields ﬂow velocity only,
conversion to volumetric ﬂow requires exact knowledge of
the vessel lumen dimensions, i.e., the cross-sectional area,
that can be obtained through either quantitative coronary
angiography (QCA) or intravascular ultrasound (IVUS)
[32, 96, 114].
The measurements need to be performed during maxi-
mal pharmacological vasodilatation induced either
regionally (i.e., intracoronary adenosine bolus dose 30–60
or 20–30 lg for left or right coronary artery, respectively,
or papaverine 15 or 10 mg, respectively) or systemically
(i.e., intravenous adenosine dose 140 lgk g
-1 min
-1 or
dipyridamole dose 0.56 mg kg
-1) to achieve minimal
coronary resistance [56]. It should be noted that the level of
vasodilatation induced with dipyridamole is slightly less
than with adenosine, leading to small differences in mini-
mal hyperemic CMVR [15]. Furthermore, vasodilatation
induced with these pharmacological vasodilating agents
(i.e., causing uncoupling between perfusion and metabolic
demand) appears to somewhat exceed the physiologically
mediated response (i.e., retained coupling between perfu-
sion and metabolic demand) (Fig. 1)[ 50, 118]. Of interest,
alpha-adrenergic-mediated coronary vasoconstriction may
even precipitate an increase in CMVR [39, 40]. Under
physiologic circumstances, there is very little alpha-
adrenergic coronary vasomotor tone at rest, and hyperemic
blood ﬂow is only somewhat blunted [69]. Under condi-
tions such as endothelial dysfunction and atherosclerosis,
however, alpha-adrenergic-mediated coronary vasocon-
striction is enhanced [6, 53, 120]. In patients with estab-
lished coronary artery disease, alpha-adrenoceptor
activation induces augmented coronary vasoconstriction,
which is powerful enough to induce myocardial ischemia
[6, 89]. Both, alpha1- and alpha2-adrenoceptors mediate
such coronary vasoconstriction, with alpha2-adrenoceptors
more predominant in the microcirculation [17, 41]. Nota-
bly, reﬂex alpha-adrenergic coronary vasoconstriction is
also elicited during coronary interventions [34, 49], and
Basic Res Cardiol (2009) 104:485–498 487
123this contributes to postinterventional contractile dysfunc-
tion [36, 37]. The distribution pattern of increased CMVR
under these ischemic conditions appears to be very heter-
ogeneous [90]. Infusion of adenosine subsequently lowers
minimal CMVR and alleviates signs and symptoms of
ischemia [89, 90]. Antagonizing the a-adrenergetic recep-
tors may further enhance hyperemic perfusion on top of the
aforementioned vasodilating agents, particularly during
pathological conditions such as ischemia, in part mediated
by the prolongation of diastolic perfusion time [35, 39, 64].
Finally, although beyond the scope of this review, endo-
thelium coronary microvascular function can be tested
separately through endothelium-dependent-mediated
vasodilating agents, such as intracoronary acetylcholine.
Using pressure–ﬂow relations measured within a coro-
nary artery, the diastolic coronary pressure–ﬂow (P–F)
relationship can also be used to assess microvascular
resistance. This relationship is essentially linear at perfu-
sion pressures [40 mmHg but is appreciably curved at
lower pressures. The curvilinearity is explained by gradu-
ally declining diameters of microvascular vessels at low
pressures. Diastolic coronary ﬂow stops at a coronary
pressure far above right atrial pressures. The zero ﬂow
pressure is considered as a back pressure that affects cor-
onary driving pressure. The mechanism and interpretation
of the zero ﬂow pressure are still a matter of debate [59,
100]. Two theories have been proposed to explain this
phenomenon: a vascular waterfall theory and an intramyo-
cardial pump model theory. In the former, vascular col-
lapse is assumed to take place at very low pressure. The
latter model is explained by the fact that the intramyocar-
dial blood volume and blood pressure change more slowly
than arterial pressure due to large time constants for
charging and discharging the intramyocardial compliance.
So, intramyocardial blood is still streaming even when
epicardial coronary blood ﬂow has stopped. The curvilin-
earity of the P–F relation implies that microvascular
resistance does not remain constant during one cardiac
cycle. Furthermore, to determine the zero ﬂow pressure, a
very long diastole is needed; in a normal clinical situation,
the next cardiac cycle is starting long before coronary ﬂow
of the previous cardiac cycle has become zero. For these
reasons, the P–F relation and zero ﬂow pressure are very
hard to use in clinical practice and therefore will not be
further discussed in this review. In clinical studies, right
atrial pressure can be advocated as an estimate of coronary
back pressure to calculate CMVR.
Strengths and limitations
The major advantage of the catheter-based approach is the
fact that coronary angiography can be performed to
exclude obstructive atherosclerosis of the epicardial arter-
ies during the same session as the CMVR measurements.
Moreover, in the presence of an epicardial obstructive
stenosis, regional CMVR can be determined by assessing
pressure and ﬂow distal to the lesion [72]. In these
instances, distal pressure measurements can distinguish
coronary epicardial from microvascular resistance. The
contribution of the epicardial stenosis to total coronary
resistance can additionally be evaluated by determining the
pressure drop over the epicardial stenosis (fractional ﬂow
resserve, FFR) [71, 72]. Finally, acute effects of (coronary)
interventions on CMVR can be monitored, particularly in
target vessel coronary arteries [89, 112]. There are, how-
ever, several limitations that deserve attention.
First, the thermodilution technique has drawbacks. Sta-
ble positioning of the catheter, especially in the coronary
sinus, can be difﬁcult [28, 73, 117]. Furthermore, absolute
quantiﬁcation of ﬂow requires accurate registration of the
temperature and volume of the injected indicator (saline) at
the injection and the downstream temperature recording at
the distal site. These types of measurements have proven to
be problematic and display relatively high variability, e.g.,
due to incomplete mixing of saline and blood [73, 117].
Mixing problems appear to be smaller for bolus injections
than for continuous infusion of saline [2].
Given these technical limitations, Pijls and colleagues
have developed and validated a simpliﬁed thermodilution
model where an index rather than quantitative ﬂow is
obtained by registration of the mean transit time of the
indicator, disregarding absolute temperature changes [19,
82]. Thereafter, a semi-quantitative, unit-less index of
microcirculatory resistance can be calculated [26].
Although experience is limited, mean transit time could
also be determined using X-ray densitometry [38].
Second,althoughbloodﬂowvelocitymeasurementsfrom
Doppler signals are robust, determination of the cross-sec-
tional area of the vessel for subsequent conversion to abso-
lute ﬂow remains problematic [25]. QCA requires
angiography from at least two, but preferably more, angles
and isaccompanied by time consumingpost-processing[32,
96].IVUSyieldsqualitativelyexcellentimagesandaccurate
cross-sectional area estimates, but is expensive and less
widely available [114]. To circumvent the additional cross-
sectional area imaging, a similar index of resistance as
mentionedabovehasbeenintroducedbyMeuwissenandco-
workers [75]. The so-called velocity-based index of CMVR
equals the central arterial pressure divided by ﬂow velocity
obtainedwithDopplerandisexpressedinmmHg cm
-1 s
-1.
Third, in the presence of an obstructive coronary lesion,
collateral ﬂow becomes increasingly important with
increasing stenosis severity. The above-described tech-
niques do not account for collateral ﬂow and therefore
overestimate actual microvascular resistance [1]. Although
488 Basic Res Cardiol (2009) 104:485–498
123this effect can be determined by measuring pressure and
ﬂow distal to the lesion during wedging of the coronary
artery, these measurements are cumbersome and introduce
additional room for error that hinder the interpretation of
the obtained data. Apart from these technical limitations,
the invasive nature of the procedure, exposure to ionizing
radiation, and use of nephrotoxic contrast agents are gene-
ral limitations that must also be taken into account.
Noninvasive quantiﬁcation of minimal CMVR
Noninvasive measurement of CMVR can be obtained with
positron emission tomography (PET), cardiovascular
magnetic resonance imaging (CMR), or echocardiography.
As will be discussed below, each of these imaging
modalities allows for the absolute quantiﬁcation of perfu-
sion with the aid of radiolabeled or contrast agents, and
also enable to detect regional variability [29, 33, 90, 105].
Characteristics of each modality are given in Table 1.
During these noninvasive perfusion studies, the coronary
driving pressure can simply be obtained by measuring
mean arterial blood pressure with the use of a sphygmo-
manometer. As already mentioned, systemic vasodilatation
is usually achieved by the infusion of adenosine or
dipyridamole.
Depending on the spatial resolution of the imaging
modality, perfusion and resistance can even be distin-
guished between the subendocardial and subepicardial
layers. The latter is of pathophysiological importance as
ischemia principally occurs in the subendocardium [27,
43]. Furthermore, diastolic perfusion time has proved to be
an important determinant of subendocardial ischemia and
can simultaneously be assessed using echocardiography
and CMR [27, 109].
The major disadvantage that characterizes these nonin-
vasive approaches pertains to the inability of these imaging
modalities to exclude the proximal pressure drop in
obstructive epicardial coronary artery disease to distinguish
microvascular from epicardial stenosis resistance.
Although it is important to bear in mind that coronary
microvascular dysfunction is often a global process, ref-
erence areas with relatively preserved hyperemic perfusion
can be still used to quantify CMVR. The adjacent more
severely blunted perfusion areas are then assumed to be
caused by epicardial lesions.
General considerations of perfusion quantiﬁcation
The general principle of quantitative perfusion imaging is
based on the registration of the exchange of tracer concen-
tration between arterial blood and myocardial tissue over
time, where the ideal perfusion tracer accumulates in or
clears from myocardium proportionally to MBF and is not
affected by the magnitude of ﬂow and pathophysiological
conditions [54]. For all tracers, the activity concentration in
myocardium(i.e.,thetissueresponsetotheinjectedtracer)is
dependent on the product of MBF, the tracer extraction
fraction,andthearterialinputfunction.Inotherwords,MBF
can be calculated when myocardial and arterial concentra-
tionsaremeasuredovertimeandtracerextractionfraction is
known. The latter value equals unity for completely freely
diffusible tracers, although for most tracers, the ﬁrst pass
extraction is less than 1 and declines nonlinearly relation
with increasing MBF, complicating quantiﬁcation of ﬂow.
Positron emission tomography
For PET perfusion imaging, two tracers in particular have
been well validated and are routinely used for quantiﬁca-
tion of myocardial blood ﬂow: oxygen-15 labeled water
(H2
15O) and nitrogen-13 labeled ammonia (
13NH3)[ 7, 94].
The scanning procedure for both tracers is comparable
where after an intravenous bolus injection of the perfusion
tracer simultaneously a dynamic emission is performed.
Figure 2 shows an example of such a dynamic cardiac
13NH3 PET acquisition and its corresponding time activity
curves for regions of interest derived from the LV cavity
and the myocardium.
Based on the known biological behavior of the two
tracers, kinetic compartment models have been developed
to quantify MBF in absolute terms (mL min
-1 g
-1). There
are, however, some important differences in characteristics
between H2
15O and
13NH3 MBF measurements that are
listed in Table 2. Two particular technical aspects are
worth discussing in more detail.
Table 1 Characteristics of different imaging modalities regarding
absolute quantiﬁcation of myocardial perfusion
PET CMR MCE
Radiation Yes No No
Costs High Moderate Low
Availability Limited Limited Widely
Safety Good Good Moderate
Reproducibility High NA NA
Validation kinetic model Excellent Good Fair
LV coverage Complete Incomplete Incomplete
Post-processing Parametric Manual Manual
Spatial resolution Moderate High High
LV function imaging Moderate Excellent Good
PET positron emission tomography, CMR cardiovascular magnetic
resonance imaging, MCE myocardial contrast echocardiography, LV
left ventricular, NA not available
Basic Res Cardiol (2009) 104:485–498 489
123First, H2
15O is a metabolically inert and freely diffusible
molecule which has a virtual complete extraction into the
myocardium, independent of ﬂow rate and metabolic state.
Therefore, regional differences in myocardial tissue
response are solely dependent on perfusion, rendering this
traceridealforquantiﬁcationofﬂow.Conversely,the
13NH3
extraction fraction decreases with increasing ﬂow rates,
leading to underestimation of perfusion with higher ﬂow
values unless of course they are corrected for by the tracer
compartment model. In fact, these corrections have been
thoroughly tested and perfusion values obtained with H2
15O
and
13NH3 yield comparable results and match with the gold
standard of microsphere-determined perfusion [9, 79].
Second, the modeling procedures of the tracers differ
in that perfusion is estimated from the wash-out phase of
the radiolabeled tracer in H2
15O studies, whereas for
13NH3 the myocardial uptake is used [47, 65]. These
methodological differences do not affect perfusion mea-
surements in normal myocardium [15, 79], but lead to
different ﬂow estimates in myocardium with scar tissue
[9]. As perfusion in scar tissue is negligible, uptake of
ﬂow tracers will take place in viable or normal myocar-
dium only [48]. Consequently, wash-out of H2
15Oi s
related only to the water perfusable tissue fraction so that
estimates of blood ﬂow are limited to normal or viable
myocardium. Estimates of perfusion from the wash-out
phase with H2
15O will therefore reﬂect ﬂow in viable
perfusable tissue only. In contrast, estimating perfusion
derived from tracer uptake using
13NH3 will reﬂect the
admixture of scar and viable tissue, i.e., transmural per-
fusion [60]. In practice, this means that, in the presence of
scar tissue, perfusion measured with
13NH3 will yield
lower values compared with H2
15O in direct proportion to
the magnitude of the present myocardial scar. This
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Fig. 2 Serially acquired short axis PET images following the
intravenous injection of
13N-ammonia. Ten-second images are shown.
Notice in the second image the activity in the right ventricular cavity,
and visualization of the left ventricular blood pool on the next image,
and thereafter accumulation of the tracer in the myocardium and
clearance from blood. The corresponding time–activity curves for
arterial blood and myocardial tissue are also displayed. The dynamic
ﬂux of tracer from arterial blood to tissue is modeled to convey
absolute units of perfusion. Reprinted with permission from ‘PET:
molecular imaging and its biological applications’, edited by Michael
E. Phelps (2004) Springer-Verlag, New York, Inc
Table 2 Characteristics of oxygen-15-labeled water (H2
15O) and nitrogen-13-labeled ammonia (
13NH3) for PET perfusion imaging
H2
15O
13NH3 Comment
Half-life 2 min 10 min Five half-lives are required for a repeated
measure
Production Cyclotron Cyclotron An on-site cyclotron is necessary given the
short half-lifes of the tracers
Kinetics Freely diffusible;
metabolically inert
Metabolically trapped in
myocardium
Greater activity gradient between arterial
blood and myocardium for
13NH3, yielding
superior qualitative images
First pass extraction Complete Incomplete in a nonlinear fashion
with increasing MBF
Corrections for incomplete extraction of
13NH3 with increasing MBF required
Modeling quantiﬁcation
parameter
Tracer wash-out Tracer uptake Perfusable versus transmural estimates of
MBF; see text for details
490 Basic Res Cardiol (2009) 104:485–498
123technical feature has been used to quantify coronary
CMVR in residual viable myocardium after a myocardial
infarction in humans using H2
15O PET [71, 72, 107].
Strengths and limitations
For the last two decades, PET has served as the gold
standard for noninvasive absolute quantiﬁcation of myo-
cardial blood ﬂow (MBF) and CMVR [54]. Both tracers
have been shown to accurately quantify MBF in absolute
units over a wide ﬂow range and correlate well with values
obtained after injection of radiolabeled microspheres, both
at a regional and global level [9]. Furthermore, reproduc-
ibility was shown to be good [55, 77], and PET studies
have provided normal references values for both resting
and hyperemic MBF in healthy volunteers [15]. In addi-
tion, the relatively short half-life of the tracers, particularly
H2
15O (120 s), allows for serial measurements within a
single session which enables the investigation of multiple
interventions on perfusion and resistance [63]. Finally, in
recent years, parametric imaging has signiﬁcantly reduced
the post-processing time by the omission of elaborate
(manual) region of interest analysis, making this technique
increasingly operator friendly [8, 31].
On the downside, perfusion PET suffers from its limited
availability and high costs, which are mainly related to the
necessity of an onsite cyclotron and expertise regarding the
preparation and administration of the involved radiotracers.
Also, PET imaging is accompanied by exposure to ionizing
radiation, although the burden is relatively low using these
short-lived tracers. Furthermore, the spatial resolution of
PET is relatively low (*5 mm), resulting in partial volume
and spillover effects. Sophisticated kinetic modeling
parameters, however, can correct for these effects and
advances in imaging instrumentation have even enabled the
distinction between subendocardial and subepicardial per-
fusion, not only in the hypertrophied human heart but also
in the normal sized myocardial wall [61, 85, 86]. Finally,
although PET is the method of choice for noninvasive
assessment of perfusion and metabolism, it does not pro-
vide suitable anatomical information compared with CMR
and echocardiography. However, state-of-the-art hybrid
imaging systems combining PET and CT offer anatomical,
functional, and metabolic information in a single scan
session [20, 62, 91, 92, 97].
Cardiovascular magnetic resonance imaging
Although initial attempts for (semi)quantitative assess-
ment of MBF using CMR focused on velocity-encoded
phase contrast imaging of either the proximal course of
the coronary arteries or the coronary sinus [46, 110],
recent myocardial CMR perfusion imaging approaches are
mainly based on the changes in myocardial signal inten-
sities during ﬁrst pass of paramagnetic extracellular con-
trast agents, i.e., gadolinium chelates [51]. After an
intravenous bolus injection of the contrast agent, an
electrocardiogram-gated acquisition of approximately 30–
60 s is started and myocardial and arterial signal inten-
sities are recorded over time. The patient is normally
asked to suspend breathing for 10–15 s after the bolus
injection so that the initial myocardial contrast-enhance-
ment can be observed without interference from breathing
motion, although image quality is generally not affected
by the breathing motion, but causes slice misregistration.
Figure 3 displays such an imaging sequence. During the
ﬁrst pass of the contrast agent, a fraction of it rapidly
diffuses through the capillary walls into the interstitium,
where it reduces the T1 relaxation time and increases the
signal intensity of the protons surrounding the contrast
molecules. The myocardial signal intensity response to
the arterial input, however, depends not only on the
perfusion, but also on the tissue blood volume, the size of
the extravascular compartment, and the degree of capil-
lary permeability, which complicates quantitative analysis
that must account for all these unknown variables [103,
104]. Therefore, for the purpose of only determining tis-
sue blood ﬂow, a model-independent approach based on
the central volume principle of Zierler [121] was devel-
oped that focuses on the initial amplitude of the myo-
cardial tissue response, which is, in theory, related to ﬂow
only. The area under the impulse response curve repre-
sents the (dynamic) volume of distribution during the ﬁrst
pass, and can provide a measure of vascular volume if an
intravascular tracer is used. For extracellular tracers, such
as gadolinium diethylenetriaminepenta-acetic acid, the
impulse response is characterized by an initial rapid decay
related to the vascular phase of contrast transit, and a
prolonged tail that corresponds to the delayed wash-out of
tracer that has passed from the capillaries into the inter-
stitial space. The application of the model-independent
analysis based on the central volume principle requires
numerical deconvolution of the measured signal
enhancement in tissue with an arterial input function
derived from the measured signal enhancement in blood
(e.g., in the ascending aorta or the left ventricular cavity).
This model for absolute quantiﬁcation of ﬂow has sub-
sequently been validated in animal experiments by com-
paring the blood ﬂow measurements with radio-labeled
microspheres [52], and thereafter been used in more large
scaled clinical studies for the assessment of microvascular
function [81, 87].
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Myocardial perfusion imaging using CMR has the advan-
tage of high spatial resolution, no use of ionizing radiation,
the use of readily available contrast agents, and no atten-
uation problems related to, e.g., overlying breast shadow.
Furthermore, next to the information pertaining to perfu-
sion, accurate assessment of regional myocardial wall
motion and, using late-contrast enhanced images (approxi-
mately 10–15 min after injection), tissue morphology can
be obtained in the same setting [10, 57, 58]. Moreover,
advances in CMR imaging have now enabled accurate
delineation of subendocardial and subepicardial perfusion
[83, 84]. In combination with CMR-estimated diastolic
perfusion time, not only regional resistance but also some
of its determinants can be evaluated. There are, however,
some important technical limitations that hamper the rou-
tine quantiﬁcation of perfusion with CMR.
First and foremost importance, to achieve an adequate
signal-to-noise ratio of the myocardial tissue enhancement
as displayed in Fig. 3, relatively large doses of gadolinium
are administered (from 0.05 up to more than
0.1 mmol kg
-1). At these concentrations, however, the
linear relationship between the measured signal intensity in
the LV cavity and the actual contrast concentrations levels
off. Therefore, for quantiﬁcation purposes where the arte-
rial input concentrations of contrast must reliably be
deﬁned, one should use much lower doses of gadolinium,
i.e., in the order of 0.005–0.03 mmol kg
-1, to retain a
linear relation between contrast concentration and the
obtained signal. Unfortunately, these lower doses result in
decreased contrast to noise ratios and loss of the possibility
for visual analysis of the myocardial tissue response. To
circumvent this problem, Christian et al. [18] have recently
introduced and validated the so-called dual-bolus approach.
Low and high concentration bolus injections of contrast are
administered serially within a few-second interval, where
the ﬁrst is used for registration of the arterial input function
and the second for tissue response. In this manner, high
signal-to-noise tissue images are generated, additionally
allowing qualitative visual interpretation, and fully quan-
titative computation can be performed using the input
Fig. 3 CMR short axis images
(a–d) of the ﬁrst pass of
gadolinium contrast and activity
curves of contrast (expressed in
arbitrary units) plotted against
time for the arterial left
ventricular blood pool and two
myocardial regions. A perfusion
defect can be observed both
visually on the images and from
the activity registration in the
anteroseptal area, where the
peak intensity and slope of the
curve are reduced. Note that
tracer uptake in tissue occurs
just seconds after the peak
intensity of the input curve and
remains fairly stable in the
minute thereafter, as the
contrast agent resides in the
extracellular matrix after
diffusion from the capillaries.
Also note the recirculation of
contrast after 25 s that induces a
second peak in arterial blood.
Because the physiological
behavior of the tracer is
dependent on a variety of
physiological parameters that
cannot be modeled, only peak
intensity levels of arterial blood
and tissue are used to determine
perfusion in absolute terms
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123curve. In addition, the signal enhancement in tissue, despite
being much lower than in the blood pool, may still be
compromised by some saturation effects from the signal
contributed by the vascular volume fraction in tissue.
Therefore, one of the original proponents of the dual-bolus
approach recently proposed a method for nonlinear myo-
cardial signal intensity correction, but still assuming that
myocardial tissue is a homogeneous space [45]. In addition
to the dependence of the myocardial signal on the under-
lying structure of the tissue and the distribution of the
contrast agent, one should also note that the 1H signal is
not only affected by close contact with the contrast agent,
but also by the exchange of water between different spaces
in tissue, including spaces not directly accessible to the
contrast agent [23, 24, 67].
Second, post-processing requires manual deﬁnition of
myocardial regions of interest or segmentation along the
endo- and epicardial borders, which is quite time con-
suming. Although efforts are being made to map perfusion
on a pixel-by-pixel basis, these new analysis techniques are
not yet routinely applicable [30]. Furthermore, the process
of manual region delineation is complicated by patient
motion during the breath-hold acquisition. In particular, the
stress study is prone to motion artifacts that require frame
by frame adjustment of the regions of interest.
Finally, recent attention has focused on the toxicity of
gadolinium-based contrast agents, particularly in patients
with chronic renal failure where its use is associated with
nephrogenic systemic ﬁbrosis [66]. In fact, these side-
effects have restricted its use to patients with a glomerular
ﬁltration rate of at least 30 mL min
-1 [115]. Also, some
general restrictions prohibit perfusion imaging with CMR,
such as claustrophobia, myocardial arrhythmias, and
implanted devices.
Echocardiography
Myocardial contrast echocardiography (MCE) for quanti-
ﬁcation of perfusion has become feasible with the recent
development of an encapsulated microbubble contrast
agent that remains conﬁned to the intravascular space and
behaves similarly as red blood cells in terms of rheology
[68]. The microbubbles are continuously administered
intravenously in order to reach a steady state with con-
centrations in arterial blood and myocardial tissue rela-
tively constant. Subsequently, a high-power ultrasound
pulse applied within the acoustic beam destroys the bub-
bles and the void is replenished within few seconds
(Fig. 4a). The time–video intensity registration can be ﬁt-
ted to an exponential equation, i.e., y = A (1 – e
-bt),
where A represents the (mainly capillary) myocardial blood
volume and b the rate constant that indicates the ﬂow
velocity of blood (Fig. 4b) [116]. The product of the two,
therefore, provides an estimate on myocardial blood ﬂow,
which correlates with perfusion in canine experiments
[116].
True quantiﬁcation, however, is hindered by the fact that
estimated myocardial blood volume is subjected to attenu-
ation artifacts, such as the microbubbles present in the left
ventricular cavity, and heterogeneity of the acoustic beam.
Vogel et al. have recently circumvented this issue by
standardizing the myocardial blood volume signal to the
adjacent left ventricular blood pool signal (Fig. 4c). As
Fig. 4 a Example of
intravenous myocardial contrast
echocardiography, 3-chamber
view during hyperemia:
precontrast image (a), high
mechanical ultrasound pulse (b),
and subsequent replenishment
of contrast (c–h). b Example of
mono-exponential time–video
intensity curve. The slope of the
initial phase of the curve
represents the microbubble ﬂow
velocity, whereas the plateau
phase indicates blood volume.
c Region-of-interest placement
for myocardial regions with
adjacent left ventricular blood
pool in a four-chamber view of
a healthy volunteer. Reprinted
with permission from Dijkmans
et al. [21]( a, b), and from
Vogel et al. [113]( c)
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123these signals are theoretically affected to a similar degree
by these artifacts, they are ﬁltered out using this approach
[113]. Indeed, absolute quantiﬁcation of perfusion with
MCE correlated nicely with PET-obtained values in
humans [113].
Strengths and limitations
Although MCE is relatively new in the ﬁeld of perfusion
imaging and requires operator demands that are not easily
met, the potential for this technique is evident as echo-
cardiography is widely available, and is characterized by
high temporal and spatial resolution, and performs well in
additional functional cardiac imaging. Despite these
advantages, compared with PET and CMR, MCE must
currently be considered the least accurate and attractive
noninvasive perfusion imaging modality for two reasons.
First, there are some technical concerns. As commonly
known, echocardiography suffers from a poor acoustic
window in a not inconsequential percentage of patients.
In general, about 10–15% of echo exams are of poor
quality. Moreover, even when these patients have been
excluded, a recent MCE perfusion study has shown that
an additional 20% of myocardial segments were not
suitable for the analysis [21]. Furthermore, the number of
validation studies with MCE that have implemented the
above-described model is limited [21, 113]. Unfortu-
nately, the initial promising results of Vogel et al. [113]
could not be reproduced by Dijkmans and co-workers
[21], as the latter study revealed signiﬁcantly more scatter
in the obtained perfusion data as compared with PET.
One of the possible explanations for the inaccuracy of the
measurements, next to distortions in image quality, could
be that the model assumes linearity between contrast
concentrations and measured video intensity. This
assumption, however, is incorrect in the higher range of
microbubble concentrations as observed in the left ven-
tricular cavity [99, 116]. Another issue, and similar to
CMR, is the tedious post-processing procedure that
requires manual deﬁnition of regions of interest, prohi-
biting its use on a larger scale.
Second, there is an ongoing debate with respect to safety
of the microbubble contrast agent [22]. Adverse allergic
reactions have been frequently reported. Although these
side effects generally do not result in permanent damage, it
has led to regulations restricting the use of some brands in
severely cardiovascular compromised patients [22]. Use of
these agents, therefore, requires the attention of a physician
at all times. In addition, both dog [4] and human [111]
experiments have shown that the destruction of micro-
bubbles by the ultrasound beam can result in microvascular
damage. Although relatively low mechanical pulses seem
reasonably safe, they in turn may result in incomplete
bubble destruction, which reduces the quality of the study
[80].
Summary and conclusions
With the growing awareness that coronary microvascular
dysfunction is an important pathophysiological component
in many cardiac conditions, comes the necessity to
accurately assess the functional status of the microcircu-
lation [13]. In trying to achieve this goal, absolute
quantiﬁcation of perfusion and pressure to determine
minimum microvascular resistance plays a central role
[70, 118]. This review has discussed the pros and cons of
the currently available invasive and noninvasive tech-
niques regarding these measurements. It can be concluded
that the invasive approach is the preferred method in
patients with epicardial obstructive coronary atheroscle-
rosis as microvascular resistance can be determined distal
to the epicardial lesion. Also, invasive measurements are
most suitable to investigate acute effects of interventions.
The noninvasive measurements with PET, CMR, or MCE
to assess the coronary microcirculation can be used in
patients in whom obstructive coronary artery disease is
unlikely or, preferably, excluded by angiography. The
advantages of noninvasive over invasive methodology are
obvious. In particular, monitoring interventions that
potentially modulate coronary microvascular dysfunction,
which require serial measurements over longer periods of
time, should beneﬁt from a noninvasive approach. PET
was proven to be the unrivalled imaging modality for
absolute quantiﬁcation of perfusion. The introduction of
hybrid systems that combine PET with CT could be of
additional beneﬁt, as CT angiography could also exclude
epicardial coronary artery disease in these patients. Per-
fusion quantiﬁcation with CMR has rapidly evolved and,
in the hands of few experienced centers, now offers an
approach that combines absolute perfusion measurements
with detailed functional, anatomical, and morphological
cardiac information. MCE is the most accessible tech-
nique, and could theoretically be used in most research
imaging centers. Technical limitations together with rela-
tively inaccurate perfusion measurements and some safety
concerns, however, have to date restricted widespread
application of MCE.
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